ESC 365 - Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

ESC Professional Premium Access

Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

Session: Oral anticoagulation in patients with atrial fibrillation

Topic: Anticoagulants

Speaker: Doctor S. Patel (Boston, US)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Siddharth Patel

Brigham and Women's Hospital, Boston (United States of America)

0 follower

7 more presentations in this session

Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study

Speaker: Doctor M. Abou Kaoud (Tel Aviv, IL)

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Speaker: Mr M. Grymonprez (Ghent, BE)

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

Speaker: Doctor S. Deitelzweig (New Orleans, US)

Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis

Speaker: Doctor T. Chao (Taipei, TW)

Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients

Speaker: Doctor J. Kim (Seoul, KR)

Access the full session

Oral anticoagulation in patients with atrial fibrillation

Speakers: Doctor S. Patel, Doctor M. Abou Kaoud, Mr M. Grymonprez, Doctor S. Deitelzweig, Doctor T. Chao...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by